Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases

US8431695B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Stephen O'Connor · Wilmette, US
• Jacques Dumas · Neuilly-Plaisance, FR
• Wendy Lee · Hamden, US
• Julie A. Dixon · Bethany, US
• David Cantin · Hamden, US
• David Gunn · Waukegan, US
• Jennifer Burke · Newtown, US
• Barton W. Phillips · San Mateo, US
• Derek Lowe · Scotch Plains, US
• Tatiana Shelekhin · Ridgefield, US
• Gan Wang · Wallingford, US
• Xin Ma · Bethany, US
• Shihong Ying · Orange, US
• Andrea McClure · West Haven, US
• Furahi Achebe · West Haven, US
• Mario Lobell · Wuppertal, DE
• Frederick J. Ehrgott · Piscataway, US
• Christiana I. Iwuagwu · Wallingford, US
• Kyle E. Parcella · Wallingford, US

Key dates

• Filing date: Nov 2, 2006
• Grant date: Apr 30, 2013
• Expiry date: Sep 28, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer.